Canada markets open in 8 hours 28 minutes

Grifols, S.A. (GIFLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
9.410.00 (0.00%)
At close: 03:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close9.41
Bid0.00 x 0
Ask0.00 x 0
Day's Range9.41 - 9.41
52 Week Range9.41 - 23.69
Avg. Volume900
Market Cap5.442B
Beta (5Y Monthly)0.19
PE Ratio (TTM)94.10
EPS (TTM)0.10
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 03, 2021
1y Target EstN/A
  • Reuters

    Grifols appoints executive chairman as seeks to speed recovery

    Grifols appointed an executive chairman on Monday, as the Spanish pharmaceutical company strives to recover from a pandemic-related hit and a 49% drop in its shares so far this year. Steven F. Mayer, an independent board member since 2011 and a former senior managing director of Cerberus Global Private Equity, will become executive chairman, effective immediately. The company's outgoing non-executive chairman, Victor Grifols Roura, who was chief executive from 1987 to 2016, has been named honorary chairman.

  • GlobeNewswire

    GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens

    SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombi

  • CNW Group

    Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

    Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.